V160

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Cytomegalovirus (CMV) InfectionsCytomegalovirus Infections

Phase 1

Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)

CompletedNCT03840174

Merck Sharp & Dohme LLCCytomegalovirus Infections

Start: 2019-03-08End: 2019-11-07Updated: 2023-05-06

Phase 2

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

CompletedNCT03486834

Merck Sharp & Dohme LLCCytomegalovirus (CMV) Infections

Start: 2018-04-30End: 2021-06-30Updated: 2024-01-23

Related Papers

Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.

2023-08-3134 citations

Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study

Antibodies2023-03-1012 citations